Total trials
96
Active
21
Phase 3
7
Total enrollment
26,925
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Elotuzumab | — | — | — | — | — | 1 | |
| Carfilzomib | — | — | — | — | — | 1 | |
| Lenalidomide | — | — | — | — | — | 1 | |
| Dexamethasone | — | — | — | — | — | 1 |
Next readouts
- 2029-08
Top conditions
- Adrenal Insufficiency8
- Gingivitis4
- Multiple Myeloma3
- Prostate Cancer3
- Periodontitis3
- Rare Diseases3
- Fabry Disease3
- GI Cancer2
Frequently asked questions about Wuerzburg University Hospital
- How many clinical trials does Wuerzburg University Hospital have on ClinicalTrials.gov?
- Wuerzburg University Hospital is listed as the lead sponsor on 96 clinical trials in ClinicalTrials.gov, 21 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Wuerzburg University Hospital's trials are in Phase 3?
- 7 of Wuerzburg University Hospital's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does Wuerzburg University Hospital focus on?
- Wuerzburg University Hospital's most-studied conditions on ClinicalTrials.gov are Adrenal Insufficiency, Gingivitis, Multiple Myeloma, Prostate Cancer, Periodontitis.
- When are Wuerzburg University Hospital's next clinical trial readouts?
- Wuerzburg University Hospital has 1 upcoming primary-completion readout tracked here; the soonest is “Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM”, expected around 2029-08.